Cerebral postischemic hypoperfusion is mediated by ETA receptors

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Research

Background:

• Postischemic hypoperfusion is a critical factor in brain injury following ischemic stroke.
• Nitric oxide (NO) plays a complex role in regulating cerebral blood flow (CBF) during and after ischemia.
• Endothelin-A (ETA) receptors are implicated in cerebrovascular regulation and may influence ischemic outcomes.

Purpose of the Study:

• To investigate the effect of the ETA-receptor antagonist BQ123 on postischemic hypoperfusion.
• To determine if BQ123 modifies the effects of nitric oxide synthetase inhibition on CBF recovery.
• To evaluate the potential of BQ123 in mitigating both early and late phases of postischemic hypoperfusion.

Main Methods:

• Mongolian gerbils were subjected to transient focal cerebral ischemia.
• Cerebral blood flow was monitored using laser Doppler flowmetry.
• Animals were treated with BQ123, N omega-nitro-L-arginine (NLA), or N omega-nitro-D-arginine methyl ester (a non-specific NOS inhibitor), or Ringer's solution.
• BQ123 was administered either prior to ischemia or post-ischemia.

Main Results:

• Pre-ischemic BQ123 administration reversed the early incomplete CBF recovery observed when NLA was present.
• BQ123 did not affect the late postischemic hypoperfusion when given prior to ischemia.
• Post-ischemic administration of BQ123 significantly reversed the late postischemic hypoperfusion in animals treated with NLA, N omega-nitro-D-arginine methyl ester, or Ringer's solution.

Conclusions:

• BQ123 demonstrates a dual role in modulating CBF after ischemia, depending on its administration timing and the presence of NOS inhibition.
• Targeting ETA receptors with BQ123 can improve early CBF recovery in the context of NOS inhibition.
• BQ123 holds therapeutic potential for reversing late-phase postischemic hypoperfusion, a critical period for secondary brain injury.